Pharma channel feed – Endpoints News

Pharma channel feed

Mereo bags rights to the latest AstraZeneca castoff, shifts focus; Neos rejects buyout offer

8 years ago

Merck’s bad day: $310M for NotPetya, franchise drugs take a hit and now the EMA pushes back on Keytruda

8 years ago

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

8 years ago

Brushing back biosims, a confident AbbVie outlines a blockbuster winning streak ahead for Humira

8 years ago

First Celgene, now Gilead can’t accurately forecast drug sales revenue. How bad is this?

8 years ago

In a pre-Halloween fright show, Celgene just scared the hell out of Wall Street — shares crater

8 years ago

Yes, the FDA did just slap down PTC’s Duchenne MD drug for the third time

8 years ago

Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

8 years ago

The Medicines Company brings out the ax, looking to jettison hundreds of jobs in top-to-bottom restructuring

8 years ago

What’s driving the rapid growth of the top 20 biopharma companies in the world?

8 years ago

Alexion bags a blockbuster new approval for its cash cow Soliris. Now what?

8 years ago

AbbVie antes up $225M in cash to buy into the Alzheimer's platform at Alector

8 years ago

FDA adds fresh ‘breakthrough’ for Novartis' cancer combo Tafinlar and Mekinist

8 years ago

GSK grabs FDA OK for new shingles vaccine, which will now tackle a key Merck franchise

8 years ago

Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca

8 years ago

Buzz: Will Brent Saunders split up Allergan if he loses the Restasis patent fight?

8 years ago

Seattle's Universal Cells brings Astellas into its fold of off-the-shelf cell therapy partners

8 years ago

FDA releases flurry of new, revised drug-specific guidance documents

8 years ago

Celgene’s $710M deal on mongersen implodes as Phase III Crohn's study flops

8 years ago

Unicorn hunter Vivek Ramaswamy has cooked up a new deal with AstraZeneca. But what is it?

8 years ago

After some painful R&D setbacks, J&J partners with Arcturus on a shot at a hep B cure  — shares rocket up

8 years ago

FDA follows through with a groundbreaking OK for Yescarta, Gilead's new CAR-T breakthrough

8 years ago

FDA experts shrug off retinopathy concerns, offer (near) unanimous thumbs up for Novo Nordisk's semaglutide

8 years ago

Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines

8 years ago

First page Previous page 314 315 316317318 319 320 Next page Last page